Biomedical engineers at Duke University have demonstrated a new synthetic approach that turbocharges bacteria into producing ...

Proteins are the workhorses that keep our cells running, and there are many thousands of types of proteins in our cells, each performing a specialized function. Researchers have long known that the ...

Changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth by increasing cancer stemness in an oestrogen independent manner. Targeting vimentin and/or the long ...

Collagen, the body's most abundant protein, has long been viewed as a predictable structural component of tissues. However, a new study challenges that notion, revealing an unexpected confirmation in ...

She has spent most of her career counseling patients with diabetes, across all ages. Protein is needed to build and maintain healthy muscles, bones, and skin. Although we most commonly associate ...

Once confined to sportsmen and women, high-protein diets are now commonplace – with Paleo, Atkins, Zone and Dukan advocating that people eat large quantities of fish, meat, eggs, nuts and cheese ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

This depends on the type of enzyme. The enzyme pepsin breaks down proteins in the acidic conditions of the stomach. Pepsin has an optimum of pH 2.5 and a working range of between pH 1-4.

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

The European Commission has become the first regulator worldwide to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease ...

Dupixent blocks the actions of two proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13). Adbry specifically targets interleukin-13 (IL-13). Both these immune system molecules are thought to ...